Home > Oncology > WCLC 2019 > Other Thoracic Malignancies > Novel Targets in Mesothelioma May Aid in Developing Treatment Strategies

Novel Targets in Mesothelioma May Aid in Developing Treatment Strategies

Conference
WCLC 2019
Trial
Phase 2, ADAM

Malignant pleural mesothelioma exhibits characteristic changes in microRNA (miRNA) levels, and they are predominantly downregulated. Many have a tumour suppressor function; some are overexpressed and appear to function as onco-miRNAs. These changes in miRNA expression provide avenues to develop new therapeutic approaches.

Whilst the majority of miRNA studies in malignant pleural mesothelioma have focused on miRNA mimics, recent studies suggest that antisense inhibitors have similar potential. The recent FDA approval of the first siRNA therapy –together with ongoing clinical trials of a number of miRNA mimic drugs– means that gene silencing drugs have moved from concept to reality. Continued preclinical studies and early phase clinical trials are needed to determine the true potential of miRNA-targeting in the treatment of malignant pleural mesothelioma [1].

Another field of interest is CDKN2A/MTAP deletion; this is the most common copy number altera...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on